Objective: The purpose of this narrative review was to summarize available data on testosterone levels in normal, healthy adult males and females, to provide a physiologic reference framework to evaluate testosterone levels reported in males and females with conditions that elevate androgens, such as disorders of sex development (DSD), and to determine the separation or overlap of testosterone levels between normal and affected males and females.
| INTRODUC TI ON
Anabolic steroids, especially testosterone, have a long history of abuse in sports for performance enhancement and competitive advantage in both male and female athletes. [1] [2] [3] [4] Because of the known anabolic effect of hormones on muscle, the use of anabolic agents such as testosterone, other androgenic steroids, and growth hormone that might enhance athletic performance have been prohibited by the World Anti-Doping Agency and other sports organizations.
In addition to these exogenous sources of anabolic agents, there is recognition that endogenous androgenic steroids may also be elevated in certain clinical conditions. This review aims to compare the testosterone levels associated with such conditions with reference to the normal testosterone levels in healthy men and women. As this review is solely concerned with biologic characteristics, especially testosterone levels, we have used the terms "male" and "female" in their biologic sense. Individuals' legal or gender identity may not conform to that biology. We have used the term "normal" in its scientific or statistical sense.
Recently, a few athletes competing in events classified for women have been found to have a male genotype with variable degrees of androgenization, that can vary from a nearly normal female to male phenotype, with testosterone levels in the adult male range.
This can occur in genetic males with a disorder of sex development (46XY DSD). These are rare conditions in which a genetic mutation affects cellular enzymes involved in the production of testosterone and the more potent androgen, dihydrotestosterone (DHT) or impairs androgen receptors that control cellular and tissue responses to androgens. There are two notable conditions: 5-alpha reductase deficiency, type 2 (5ARD2) which impairs the conversion of DHT from testosterone 5, 6 and androgen insensitivity syndrome (AIS)
caused by mutations of the androgen receptors for testosterone and DHT in tissues. 7 Because genetic males with DSD may show female phenotypic features, especially in the case of AIS, the question has been raised as to whether male athletes who have a 46XY DSD should compete in sports as men or women.
Polycystic ovary syndrome (PCOS) is another notable condition in genetic (XX) females, which is characterized by excessive ovarian production of androgens. 8, 9 This condition is included for comparison with DSD, as the affected females with PCOS are genetic and phenotypic females. The elevated levels of testosterone in these females can lead to hyperandrogenism, a clinical disorder characterized variably by hirsutism, acne, male-pattern balding, metabolic disturbances, impaired ovulation and infertility. PCOS is a common condition, affecting 7%-10% of premenopausal women. 9 Females with PCOS demonstrate a range of clinical presentation from mild hyperandrogenism and irregular menses to severe hirsutism and acne with marked oligomenorrhea and failure to ovulate, but seldom exhibit full virilization (eg, clitoromegaly).
Another form of DSD in genetic females (46XX DSD) is 21-hydroxylase deficiency (21OHD), the most common form of congenital adrenal hyperplasia (CAH). 10, 11 Males and females with 21OHD have enzymatic defects in cortisol production by the adrenal gland, which can lead to deficiencies of cortisol and aldosterone, resulting in increased adrenocorticotropic hormone The testosterone levels in normal, healthy males and females as reported are shown in Table 1 . The testosterone levels in the genetic males with 5ARD2 and AIS are shown in Table 2 . 7, [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] These values are from individuals with a range of phenotypes and varying degrees of virilization.
| ME THODS AND RE SULTS
Most of these males showed virilization with apparent male external genitalia. However, some do show a more female phenotype, with testosterone in the normal male range. (Table 3) . 7, 28, [30] [31] [32] [33] [34] Testosterone levels were similar in males with partial AIS (PAIS) and complete AIS (CAIS). Some of the reports included pubertal males for both 5ARD2 and AIS, and their ranges overlapped with the postpubertal males.
Testosterone levels in women with PCOS (Table 4) were higher than those in normal women. [35] [36] [37] [38] The mean/median range was for which the upper end of the female range was 1.6-2.8 nmol/L (46-81 ng/dL).
35-38
Testosterone levels are not shown for females with 21OHD, Testosterone levels in affected females were 3.5-fold higher than controls.
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These results are shown in a forest plot, Figure 1 
| D ISCUSS I ON
The results from published studies reviewed show clearly that the range for testosterone levels in healthy males is distinct from that for healthy females. This is highlighted in the forest plot (Figure 1 ), which shows a marked, bimodal distribution of testosterone levels between males and females without any overlap. The weighted average lower limit of testosterone level in healthy males is 8.8 nmol/L (254 ng/dL), roughly four-to fivefold higher than the average upper limit of the testosterone level in healthy females, 2.0 nmol/L (58 ng/ dL). There is no continuum of testosterone levels from normal females to normal males.
Individuals with 46XY DSD due to 5ARD2 are genetic males who as adults typically have serum testosterone levels within the normal adult male range, as shown in Figure 1 and Table 2 . Men with PAIS show a range of phenotypes with progressive masculinization depending on the degree of androgen insensitivity.
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As children, males with 5ARD2 and PAIS may be raised either as girls or boys, depending upon whether female or male phenotype predominates, and depending upon parental, social, religious and ethnocultural considerations.
F I G U R E 1 Forest plot of testosterone ranges for women and men from reference articles. X axis Log scale for testosterone values in nmol/L (ng/dL = nmol/L multiplied by 28.82), Y axis ranges of testosterone levels for each group of women or men, top solid line for each column is the weighted 95% confidence interval for normal men and women, solid line for each study is 95% confidence interval, dotted line is absolute range. Blank spacer line below a study reference indicates an additional subset for that study
In females with PCOS, who have known hyperandrogenism, the upper limit of testosterone levels is 5.5 nmol/L (159 ng/dL), about half the lower limit in normal males. 8, 9 Females who have serum testosterone levels greater than threefold higher than the upper limit of the normal range usually have clinical evidence of virilization, such as clitoromegaly, deepening of the voice and male-pattern balding, and should undergo evaluation for androgen-secreting tumours, as adrenal or ovarian tumours, or other causes of androgen excess, as hypothyroidism, glucocorticoid resistance, and hyperprolactinemia.
Females with 21OHD (CAH) may have elevated testosterone levels in the same range as for PCOS, and they should be evaluated for other possible hormonal imbalances, such especially cortisol deficiency. 10, 39 A key issue for adult, elite athletic performance is whether testosterone levels in genetic males with 5ARD2 or AIS provide a competitive advantage if an individual with either of these 46XY DSD participates in events classified for women. This is a fair consideration in individuals with 5ARD2, where endogenous testosterone levels can be within the normal adult male range and induce normal androgenic, anabolic effects. This is less of a concern in males with AIS, where male range testosterone levels have reduced androgenic anabolic effect due to androgen receptor mutations resulting in impaired androgen action.
There have been recent cases in elite athletic events including major international championships and the Olympics, in which genetic males with 46XY DSD competed as females in women's events. However, as shown in the forest plot (Figure 1 ), there is a large, categorical difference in the distribution of testosterone levels between normal, healthy females and males, that is there is no continuum of testosterone levels. From published literature (Table 1 and As described, these normal ranges are supported by several recent publications using accurate, sensitive and reproducible LC-MS/MS measurements ( Table 1) .
16-23
The validity and use of the 10.4 nmol/L (300 ng/dL) cut-off value separating female and male athletes was recently challenged as being inappropriate, and it has been proposed that the cut-off should be higher (ie, >10.4 nmol/L) or there should be no cut-off between male and female athletes. 42 The rationale for this is unclear, and establishment of any firm cut-off has been suspended pending further data and discussion, regarding acceptable levels of testosterone in female athletes. [42] [43] [44] The distinct ranges of serum testosterone levels presented in these studies should inform the discussion of cut-offs between males and females.
The relatively small number of women who have serum testosterone levels within or near the adult male range, may be genetic males with 46XY DSD, specifically males with 5ARD2 or AIS.
Females with hyperandrogenism due to PCOS or CAH usually have testosterone levels within the normal adult female range, but levels above the normal female range are observed and can approach the lower limit of the normal male range, which is about four-to fivefold higher the upper limit in normal females. Reliable tests are available that can provide useful diagnostic information regarding underlying conditions in individuals with a female phenotype who have a testosterone level above the upper limit for females and approaching or within the male range. How best to apply such information in competitive athletes is yet to be determined.
Consideration of testosterone levels is important as recent data support the divergence in athletic performance between males and females as due in part to the different levels of testosterone.
The divergence in athletic performance between men and women at puberty when serum testosterone levels diverge, has been well demonstrated, 45 and is a natural and well recognized progression to adulthood. Also, recent studies of androgen levels in elite athletes have suggested that female athletes with high testosterone levels, free or total, may have a significant competitive advantage over those with low testosterone levels. 15, 46 Further controlled studies in both males 47 and females 48 have shown significant increases in muscle mass and strength, and a clear dose-response effect with administration of increasing amounts of exogenous testosterone.
| CON CLUS ION
Based on the data summarized from published reports, it is clear that the normal adult female and male testosterone range differ markedly with a bimodal distribution, the lower limit of the male range being approximately four-to fivefold higher than the upper limit of the female range. These results do not support an acceptable upper testosterone limit in female athletes of 10.4 nmol/L (300 ng/dL) or higher. Genetic males with 5ARD2, CAIS and PAIS, whose phenotype at birth was ambiguous or female, have testosterone levels within or near the normal male range. In adult genetic males with 5ARD2, elevated endogenous testosterone levels are likely associated with enhanced athletic performance relative to genetic females. In genetic males with PAIS, tissues do not respond normally to male range endogenous testosterone levels so these levels may not be associated with enhanced athletic performance. Males with CAIS are typically phenotypic females.
In conclusion, existing studies strongly support a clear bimodal distribution of serum testosterone levels in females compared to males. These data should be considered in the discussion of female competition eligibility and classification of genetic males with possible DSD (5ARD2, PAIS, and CAIS) or genetic females with hyperandrogenism (PCOS and CAH). 
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